GALT (Galectin Therapeutics Inc.) Quarterly EPS earnings growth

Corporate company logo of Galectin (GALT)

Galectin Therapeutics (GALT) is systematically deploying liquid assets toward clinical trials, as evidenced by the quarterly EPS trend; an analysis on GURU.Markets reveals that -16.30 describes the current status of this metric. The business foundation is the innovative Belapectin designed to combat liver cirrhosis. Successful registration of the drug will grant the company monopoly pricing power within this niche.

galectintherapeutics.com (GALT) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/15/2026

GALT (Galectin Therapeutics Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Quotes Galectin Therapeutics, Inc.|GALT - Price Target Chart
- business market valuation indicators:
Market Capitalization Galectin|GALT - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Galectin Therapeutics|GALT - Accounting Value of Company|Market Capitalization to Book Value Ratio galectintherapeutics.com|GALT - Company Balance Sheet Assets
- company liabilities and liquidity data:
Total Debt to Capital Galectin Therapeutics|GALT - Long-Term Debt to Capital|Short-Term Debt to Equity Galectin Therapeutics, Inc.|GALT - Company Debts|Debts to Book Capitalization Galectin|GALT - Long-Term Debt|Company Short-Term Debts Galectin Therapeutics|Quick Liquidity Indicator galectintherapeutics.com
- earnings and market multiples details:
GALT - Profit After Payment of Taxes|Projected Future Earnings Galectin Therapeutics|GALT - Business Payback Period|Future Price to Earnings Galectin Therapeutics|GALT - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Galectin Therapeutics Inc.|GALT - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Galectin Therapeutics|GALT - Earnings per share for the last four quarters|Quarterly EPS earnings growth galectintherapeutics.com|GALT - Earnings per share increase in current year|Earnings growth forecast for next year Galectin Therapeutics
- sales revenue and business income indicators:
GALT - Company Total Revenue|Company Projected Revenue Galectin|GALT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Galectin Therapeutics Inc.|GALT - Sales Growth YoY (TTM)
Fundamental valuation:Galectin Therapeutics, Inc. - GALT
Flagship merchandise of galectintherapeutics.com

Galectin Therapeutics (GALT) focuses on developing a unique drug for the treatment of NASH with the potential for monopoly pricing power. This indicator measures the percentage change in net earnings per share compared to the same quarter of the previous year. Analyzing relative quarterly EPS dynamics allows for the identification of R&D cost management efficiency. An upward trend in the curve signals a transition toward scalable profits. The stability of this metric determines long-term investor confidence in the company's capital.

Analysis of competing companies

ARWR (Arrowhead Pharmaceuticals Inc) - Year-over-year net earnings per share growth for the last 12 months|MIRM (Mirum Pharma) - Year-over-year earnings per share growth for the last twelve months|DVAX (Dynavax Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months arbutusbio.com ABUS|Quarterly EPS earnings growth IVA|GYRE (Gyre Therapeutics) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ASMB (Assembly Bio)|Net earnings per share growth for the trailing year Genfit Corp|DRRX: Year-over-year net earnings per share growth for the last 12 months|ALGS: Year-over-year earnings per share growth for the last twelve months|biovieinc.com (BIVI) - Year-over-year earnings per share growth for the last twelve months|GLMD (Galmed Pharma) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months ENDRA|hepionpharma.com (HEPA) - Year-over-year net earnings per share change for the last twelve months